会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • COMBINED CHEMICAL/BIOLOGICAL AGENT MASS SPECTROMETER DETECTOR
    • 组合化学/生物试剂质谱仪检测仪
    • WO2004040612A2
    • 2004-05-13
    • PCT/US2003/010815
    • 2003-04-09
    • JOHNS HOPKINS UNIVERSITYCOTTER, Robert, J.
    • COTTER, Robert, J.
    • H01J
    • H01J49/424H01J49/0013H01J49/40
    • A mass spectrometer including an ion source, a detector, a first end cap electrode arranged proximate to the ion source, a second end cap electrode arranged proximate the detector, and a ring electrode arranged between the first and the second end cap electrodes. The ring electrode can be either connected to a radio-frequency voltage source or to a constant voltage source. When the ring electrode is connected to the radio-frequency voltage the first end cap, the second end cap and the ring electrode form an ion trap and the mass spectrometer operates as an ion trap mass spectrometer. When the ring electrode is connected to a constant voltage the mass spectrometer operates as a time-of-flight mass spectrometer.
    • 一种质谱仪,包括离子源,检测器,靠近离子源设置的第一端盖电极,布置在检测器附近的第二端盖电极,以及布置在第一和第二端盖电极之间的环形电极。 环形电极可以连接到射频电压源或恒定电压源。 当环形电极连接到射频电压时,第一端盖,第二端盖和环形电极形成离子阱,质谱仪作为离子阱质谱仪工作。 当环形电极连接到恒定电压时,质谱仪作为飞行时间质谱仪工作。
    • 9. 发明申请
    • BIOMARKERS OF CARDIAC ISCHEMIA
    • 心脏缺血的生物标志物
    • WO2012122094A3
    • 2012-11-08
    • PCT/US2012027711
    • 2012-03-05
    • UNIV JOHNS HOPKINSCOTTER ROBERT JJELINEK CHRISTINEVAN EYK JENNIFER E
    • COTTER ROBERT JJELINEK CHRISTINEVAN EYK JENNIFER E
    • G01N33/68C07K14/76
    • C12Q1/34C07K14/765G01N2800/324
    • The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing cardiac ischemia. In a specific embodiment, a method for diagnosing acute cardiac ischemia in a patient comprises the steps of (a) measuring the levels of one or more post-translationally modified and unmodified serum albumin peptides in a sample collected from the patient using SRM-MS, wherein the post-translationally modified peptides are phosphorylated and/or cysteinylated; (b) comparing the levels of the measured one or more post-translationally modified serum albumin peptides to the levels of the measured one or more unmodified serum albumin peptides; and (c) correlating the compared levels to a patient having ACI or to a patient not having ACI, thereby providing the diagnosis.
    • 本发明涉及生物标志物领域。 更具体地说,本发明涉及用于诊断心脏缺血的生物标志物。 在具体的实施方案中,用于诊断患者的急性心脏局部缺血的方法包括以下步骤:(a)使用SRM-MS测量从患者采集的样品中一种或多种翻译后修饰和未修饰的血清白蛋白肽的水平, 其中所述翻译后修饰的肽被磷酸化和/或半胱氨酸化; (b)将测量的一种或多种翻译后修饰的血清白蛋白肽的水平与测量的一种或多种未修饰的血清白蛋白肽的水平进行比较; 和(c)将比较的水平与具有ACI的患者或不具有ACI的患者相关联,从而提供诊断。
    • 10. 发明申请
    • BIOMARKERS OF CARDIAC ISCHEMIA
    • CARDIAC ISCHEMIA的生物标志物
    • WO2012122094A2
    • 2012-09-13
    • PCT/US2012/027711
    • 2012-03-05
    • THE JOHNS HOPKINS UNIVERSITYCOTTER, Robert J.JELINEK, ChristineVAN EYK, Jennifer E.
    • COTTER, Robert J.JELINEK, ChristineVAN EYK, Jennifer E.
    • G01N33/68C07K14/76
    • C12Q1/34C07K14/765G01N2800/324
    • The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing cardiac ischemia. In a specific embodiment, a method for diagnosing acute cardiac ischemia in a patient comprises the steps of (a) measuring the levels of one or more post-translationally modified and unmodified serum albumin peptides in a sample collected from the patient using SRM-MS, wherein the post-translationally modified peptides are phosphorylated and/or cysteinylated; (b) comparing the levels of the measured one or more post-translationally modified serum albumin peptides to the levels of the measured one or more unmodified serum albumin peptides; and (c) correlating the compared levels to a patient having ACI or to a patient not having ACI, thereby providing the diagnosis.
    • 本发明涉及生物标志物领域。 更具体地,本发明涉及可用于诊断心脏缺血的生物标志物。 在一个具体实施方案中,用于诊断患者急性心肌缺血的方法包括以下步骤:(a)测量使用SRM-MS从患者收集的样品中的一种或多种翻译后修饰和未修饰的血清白蛋白肽的水平, 其中所述翻译后修饰的肽被磷酸化和/或半胱氨酰化; (b)将所测量的一个或多个翻译后修饰的血清白蛋白肽的水平与所测量的一种或多种未修饰的血清白蛋白肽的水平进行比较; 和(c)将比较的水平与具有ACI的患者或不具有ACI的患者相关联,从而提供诊断。